GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
The future of ViiV Healthcare's HIV business is injectable.
By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around...
Continue Reading →
